Detailed Information

Cited 49 time in webofscience Cited 57 time in scopus
Metadata Downloads

Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: Neither treatment duration provides acceptable eradication rate in Korea

Authors
Kim, Byeong GwanLee, Dong HoYe, Byong DukLee, Kwang HyuckKim, Beung WookKim, Sang GyunKim, Sang WooKim, Sung KookKim, Jae J.Kim, Hak YangPark, Jong JaePark, Chang YoungBaik, Gwang HoLee, Yong ChanLee, Jun HaengLee, Jin HyugChun, Hoon JaiHahm, Ki BaikHong, Su JinLee, Sang WooJung, Hyun Chae
Issue Date
Feb-2007
Publisher
BLACKWELL PUBLISHING
Keywords
Helicobacter pylori; first line treatment; eradication rate
Citation
HELICOBACTER, v.12, no.1, pp.31 - 35
Indexed
SCIE
SCOPUS
Journal Title
HELICOBACTER
Volume
12
Number
1
Start Page
31
End Page
35
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/18116
ISSN
1083-4389
Abstract
Background Although triple combination therapy containing a proton pump inhibitor (PPI) and two antibiotics is considered as a standard regimen for the first-line anti-Helicobacter pylori treatment, there are still debates on the ideal duration of treatment. The aim of this study was to compare the efficacies of 7-day and 14-day PPI-containing triple therapy. Materials and Methods This study was performed in a randomized, multicenter, prospective manner. After upper gastrointestinal endoscopy, H. pylori-infected patients with a gastric ulcer and/or a duodenal ulcer were randomly assigned to a PAC7 group (omeprazole 20 mg or equivalent dose of other PPIs, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days) or to a PAC14 group (the same regimen as the PAC7 group but for 14 days). H. pylori status was evaluated by C-13 urea breath test 5 weeks after anti-ulcer treatment completion. Results A total of 598 patients were enrolled; 337 were randomized to the PAC7 group and 261 to the PAC14 group. The two groups were comparable in terms of baseline characteristics. The eradication rates of the PAC7 group were not inferior to those of the PAC14 group in both intention-to-treat analysis (71.2% vs. 75.5%) and per-protocol analysis (83.6% vs. 86.6%). Incidences of adverse events were comparable. Conclusions Although the 7-day PPI-containing triple anti-H. pylori therapy is not inferior to the 14-day therapy, neither treatment duration provides acceptable eradication rate reaching 90% in per-protocol analysis. New combination regimen with higher efficacy should be developed as a first-line eradication therapy for H. pylori in Korea.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Sang Woo photo

Lee, Sang Woo
안산병원 (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE